BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
Phase 1
Terminated
- Conditions
- Metastatic Hepatocellular CarcinomaStage IVA Hepatocellular Carcinoma AJCC v8Unresectable Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Stage IVB Hepatocellular Carcinoma AJCC v8
- Interventions
- Drug: IDO1 Inhibitor BMS-986205Biological: Nivolumab
- First Posted Date
- 2018-10-04
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Edward Kim
- Target Recruit Count
- 8
- Registration Number
- NCT03695250
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy
Not Applicable
Completed
- Conditions
- Colon Adenocarcinoma
- Interventions
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Edward Kim
- Target Recruit Count
- 6
- Registration Number
- NCT02569723
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
Phase 1
Completed
- Conditions
- Duct Cell Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage III Pancreatic CancerStage IV Pancreatic CancerUnspecified Adult Solid Tumor, Protocol SpecificAcinar Cell Adenocarcinoma of the Pancreas
- Interventions
- First Posted Date
- 2013-08-16
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Edward Kim
- Target Recruit Count
- 26
- Registration Number
- NCT01924260
- Locations
- 🇺🇸
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
© Copyright 2025. All Rights Reserved by MedPath